Ajinomoto BioPharma Services
Ajinomoto Bio-Pharma Services offers comprehensive capabilities for small molecule APIs and biologics production, from process development and cGMP manufacturing to aseptic fill finish, including cytotoxics. As a global CDMO, we provide the adaptive solutions, responsive service, trusted partnership and peace of mind you’ve come to rely on. Ajinomoto Bio-Pharma Services is establishing itself as a premier, US-based provider for high-containment bioconjugate manufacturing, as well as fill and finish services for both Highly Potent Active Pharmaceutical Intermediates (HPAPI) and Antibody Drug Conjugates (ADC).
NJ Bio is a US-based CRO that provides high-quality integrated chemistry and biology services for bioconjugations and ADCs to biotech and pharmaceutical companies – from start-up to big pharma. Main service areas include linker-payload synthesis for ADCs, bioconjugations and antibody-drug conjugates as well as bioassay and bioanalytical services. With our expertise and experience in the ADC field, we strive to create value for our clients by advancing their programs. Please contact firstname.lastname@example.org or visit our website.
Synaffix is a biotech company with a proprietary, clinical-stage ADC platform technology enabling ADCs with improved therapeutic index compared to all 3 major clinical-stage ADC technologies.
Our consolidated technology platform includes GlycoConnect™ antibody conjugation, HydraSpace™ polar spacer and toxSYN™ linker-payload technologies, which can be accessed together by any company with an antibody, to develop their own proprietary, best-in-class ADC.
Our technology out-licensing business has already translated into 3 clinical-stage ADCs, at least 15 distinct ADC programs being developed across our 9 partners and well over $3Bn in total potential value from our out-licensing deals.
WuXi XDC, a WuXi Biologics subsidiary, is a joint venture between WuXi Biologics and the WuXi AppTec subsidiary, WuXi STA, providing end-to-end contract development and manufacturing of bioconjugates including antibody-drug conjugates (ADCs). Our open access bioconjugation platform accelerates and transforms the discovery, development, and manufacturing of bioconjugates, ‘Linking innovation to health’, enabling our global healthcare partners and benefiting patients worldwide, with the most comprehensive capabilities and technologies in the biologics industry.
AbTis’ proprietary next-generation ADC linker technology enables specific number of payloads to bind to specific sites without antibody engineering. ADC linker is one of the major factors to influence efficacy, safety and CMC of ADC. AbTis’ technology employs a linker binding to specific site of antibody for payload conjugation without antibody engineering. It can bind a certain number of payloads to a specific site (DARs 2, 4, 8 are made). Its technology utilizes proximity effects to bind payloads to the lysine on Fc site of antibody. AbTis has its ADC pipelines, such as Claudin18.2 and Her2 ADCs and antibody-radioisotope conjugates.
Abzena is a life science group with headquarters in the UK, and chemistry and manufacturing sites in the US. Abzena’s complimentary services and technologies in chemistry, biology and manufacturing, are applied to the selection, development and manufacture of better biopharmaceuticals. Abzena works with most of the top 20 biopharmaceutical companies and academic groups all over the world and is focused on enabling the development of better treatments for patients. Abzena’s technologies have enabled many of its customers to progress products through to clinical development. Abzena was created through the incorporation of Antitope, PacificGMP, PolyTherics and The Chemistry Research Solution (TCRS); all of whom now trade as Abzena.
Ardena is a fully integrated pharmaceutical CDMO with a core focus on bringing molecules to the clinics. We offer drug development, manufacturing, logistics and (bio)analytical services to pharmaceutical customers globally. In parallel, we work with our customers to compile their regulatory dossier to fast-track their product towards compliance.
Ardena is uniquely positioned to offer quantitative bioanalysis from discovery research through GLP compliant preclinical assessments to late-stage clinical development. As such, we have supported numerous programs to assess the PK and immunogenicity of various ADCs using ligand binding assays as well as (hybrid) LC-MS/MS analysis.
BSP Pharmaceuticals is a Contract Development and Manufacturing Organization fully dedicated to antineoplastic drugs, designed to handle the complexity of biopharmaceutical products and offering customized services to support its client from development to commercial manufacturing of injectables and oral formulations. BSP Pharmaceuticals is focused on innovative therapies such as Proteosome Inhibitors, Antibody Drug Conjugates (ADCs) , Liposomal formulations, handling the major platforms of ADC compounds currently in clinical and commercial phase.
Glyco T Therapeutics
Heidelberg Pharma GmbH is a pharmaceutical company with a dual business model: (A) Providing preclinical drug development services in general with a special focus on the development of ADCs. Heidelberg Pharma has ample experience in providing antibody-drug conjugate related services to its clients. (B) Development of novel therapeutics in oncology based on its own proprietary 2nd generation ADC technology based on a novel toxin.
Heraeus, the precious metals and technology group headquartered in Hanau, Germany, is a global, private company with 160 years of tradition. Our fields of competence include precious metals, materials, and technologies, sensors, biomaterials, and medical products, as well as dental products, quartz glass, and specialty light sources. With product revenues of €4.1 billion and precious metal trading revenues of €17.9 billion, as well as more than 12,900 employees in over 120 subsidiaries worldwide, Heraeus holds a leading position in its global markets.
IntoCell is a Korea-based biotechnology company dedicated to the development and commercialisation of novel antibody drug conjugate platform technologies. The company has developed a state of the art linker technology comprising of a novel self-immolative group based on OHPAS (Ortho-Hydroxy Protected Aryl Sulfate) chemistry that works with a wide variety of phenolic and non-phenolic payloads. The OHPAS linker is designed to release phenolic payloads through intramolecular cyclization, mediated by ortho-hydroxyl group temporarily blocked by a triggering group. The technology has been extended to non-phenolics by introducing a phenolic spacer. The linker, with or without phenolic spacer, has been applied to full ADCs, which showed excellent dose dependent efficacy both in vitro and in vivo.
LegoChem Biosiences is a clinical stage biotech with expertise in medicinal chemistry. It has several antibiotic programs for infectious disease with urgent needs and drugs in oncology and anti-fibrosis. It has extended its expertise to ADC and developed next-generation site-specific ADC platform with novel linker that improves stability of ADCs in blood circulation, effectively prevents premature drug release, efficiently facilitates liberation of the drug at targeted tumor cells and ultimately shows significant improved therapeutic index.
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We perform ADC sample preparation, small scale development services, customized facility design, and superior scale up of early stage processes for late stage and commercial supply. Backed by a strong reputation for industry leading analytical capabilities and quality control, Lonza can also aide in driving quick development and improving marketability of the industry’s high potential future therapies Contact email@example.com or visit
Mersana is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop novel ADCs with optimal efficacy and safety to meaningfully improve the lives of people fighting cancer. Mersana’s lead candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b being studied in UPLIFT, a single-arm registration strategy, in platinum-resistant ovarian cancer and in a Phase 1 study in NSCLC. XMT-1592, a Dolasynthen ADC targeting NaPi2b, is in a Phase 1 dose escalation study. Mersana’s preclinical programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, a STING-agonist ADC developed using its Immunosynthen platform.
MilliporeSigma is the leading Life Science company, providing solutions as a strategic partner to help advance the promise of life saving therapies. We have the largest offering of products for formulations, actives and biotechnology processes. Our joint ADC offering includes a full range of integrated contract manufacturing services for drug development and manufacturing that spans conjugation, mAbs, linkers and payloads. To fit your ADC manufacturing needs, we offer a comprehensive processing portfolio from cell culture media to buffers, salts and stabilizers and from chromatography to TFF equipment, including single-use templates.
NOF CORPORATION is the leading commercial supplier of drug delivery products such as activated PEGs, lipids and ultrapure Polysorbates 20 and 80. Our cutting edge products include single molecule PEG linkers for ADCs “PIREBRIGHT Series” and SS-lipids for nucleic acid and gene delivery “COATSOME SS Series”.
Novasep has been a leading contract service provider in the ADC arena for more than 10 years and provides unique services for the development, clinical supply and commercial manufacture of antibody-drug conjugates including the payload, the linker and the monoclonal antibody.
Our commitment to ADCs is underlined by the recent €11M investment in a stand-alone bioconjugation unit at our Le Mans site in France. The site has more than 30 years of experience in synthesis & purification of cytotoxics using industrial chromatography.
Olon is an Italian company world leader in the Active Pharmaceutical Ingredients (APIs) production, using synthetic and biological processes for Generic market as well as in Contract Development and Manufacturing (CDMO).
With a 2020’s Turnover of 530 Mio$, OLON supplies 34 Chemical Intermediates and more than 295 APIs for the Generic market.
Thanks to all the 2.300 employees, and to highly qualified R&D team – more than 200 people – OLON can offer complete integrated packages and services to support the full development of APIs based on strong knowledge in both Chemical and Biological process, all of them under a full cGMP and regulatory coverage. Headquartered in Italy, the Group has 11 manufacturing facilities globally.
OmniAb provides the industry's only offering with three transgenic animal species, strategically built to optimally harness the unparalleled power of Biological Intelligence. OmniAb's offerings of OmniRat®, OmniMouse®, OmniChicken®, OmniFlic®, OmniClic® and OmniTaur™ also broadened to include antigen design and other technologies that supplement the animal offerings. As a leader in transgenic animal technology, we are committed to providing technologies that enable and enhance the discovery of therapeutic antibodies.
Piramal Pharma Solutions
Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process & pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products & services, and potent solid oral drug product. Our track record as a trusted service provider with experience across varied technologies makes us a partner of choice for innovator and generic companies worldwide.
Formed in 2015, PROVEO is now a Division of Cerbios- Pharma SA focused on complete supply chain solution for Antibody Drug Conjugates (ADCs).
Thanks to the partnership with AGC Biologics and Oncotec, PROVEO offer best-in-class solutions for the integrated development and cGMP manufacturing of recombinant proteins (incl mAbs), cytotoxic drug-linker payload, conjugation, aseptic fill and lyophilization. Strengths of the three PROVEO partners secure a seamless and low risk ADC supply chain for clinical and commercial projects.
SafeBridge Consultants, Inc
SafeBridge Consultants, Inc. is the premier resource for high-level safety, health and environmental support to the pharmaceutical and biotechnology industry. Comprised of industry leaders in toxicology, analytical chemistry and industrial hygiene. SafeBridge has developed the “brand name” in the pharmaceutical industry as a leader in the field of advanced worker protection programs for potent drug handling and risk assessment for product protection. SafeBridge has locations in Mountain View, California, New York City and London, England.
The Sartorius Group is a leading international partner of the biopharmaceutical industry and the research sector. We are helping biotech scientists and engineers across the entire globe to develop and manufacture medications from the first idea to production. So more people will have access to better medicine.
Aptamer Group is the developer of custom affinity tools for the life science industry through its proprietary Optimer® platform.
Optimer binders are nucleic acid-based affinity ligands that can be used as an antibody alternative to offer novel solutions and improvements to current processes across the therapeutic, diagnostic, bioprocessing and research sectors. The Optimer platform consists of three parallel processes optimized for target type to enable scientists with the best affinity ligand for small molecules, proteins or cell targets.
Offering rapid development in just weeks, full platform compatibility and tuneable binding kinetics to ensure desired end-use performance, Optimer binders are enabling new insights and new molecules to progress life science for better healthcare for all.
Bio-Techne is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. Bio-Techne’s product portfolio, representing the biomedical research brands of R&D Systems, Novus Biologicals, Tocris, ProteinSimple and ACD, assists scientific investigations into biological processes and the nature and progress of specific diseases.
BPS Bioscience’s purpose is to advance new scientific discoveries that lead to therapies by creating innovative solutions for research. Our focus areas are immunotherapy, epigenetics, coronavirus, CRISPR, cell signaling, and others, providing 4000+ high quality recombinant cell lines, lentiviruses, proteins and all aspects of biochemical and cell-based assay development. As a primary manufacturer, we can supply products in large-scale bulk quantities, as well as contract and custom manufacturing. Our biochemical and cell-based screening services are also available to accelerate your research.
BroadPharm is a leading customer-focused biotech company in San Diego. We are dedicated to manufacturing and supplying high purity PEG reagents, ADC linkers, & Bio-labeling tools to our clients worldwide. Our ADC linker products include cleavable & non-cleavable ADC linkers, site specific ADC linkers, PEGylated and branched ADC linkers.
BroadPharm also offers IP-protected custom synthesis & conjugation for our clients in the pharmaceutical and biotech industries. We provide timely technical support to address our client’s needs & offer advice for the best use of our new products.
Cfm Oskar Tropitzsch GmbH
A German/Bavarian based company that offers a unique selection of payloads for ADCs. We provide state of the art molecules as well as contract manufactured payloads – derived from fermentation, soil, algae or chemically synthesised. Non GMP for early R&D up to cGMP for APIs made in Europe. Our reliability, flexibility, independence and reputation are our key success factors.
Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration. For more information, please visit
Exelixis is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our efforts have resulted in four approved products and we have partnered with leading pharmaceutical companies to make these available to patients worldwide. We are committed to prudently reinvesting in our business to maximize the potential of our pipeline, through both targeted business development and internal drug discovery – all to help cancer patients recover stronger and live longer.
Imagen Therapeutics is a leading provider of end-to-end in vitro pharmacology services utilizing primary patient tumor samples and have applications for both patient diagnostics and oncology drug development.
Our unique technology harnesses the power of high-content imaging to visualize treatment outcomes with the largest collection of patient-derived cell (PDC) models predictive of clinical response. For ADC applications, we can assess cell surface binding, internalization, degradation and cytotoxic readouts.
Imagen’s technology platform offers direct patient benefit with our predictRxä in vitro diagnostic tool while accelerating and de-risking drug development with predictTx drug screening offering for biopharma.
MabPlex International provides one-stop, high-quality CRO/CMO solutions for biologics (mAb and ADCs) to our global clients. We are dedicated to help our clients accelerate development process and reduce manufacture costs. MabPlex has extensive experiences in manufacturing for therapeutic antibodies and antibody-drug conjugates (ADCs). Our manufacturing facilities with large-scale disposable lines and world-class instruments are operated by well-trained professionals in full compliance with U.S, European, and Chinese GMP regulations.
Minakem is a technology driven outsourcing partner dedicated to developing and manufacturing fine chemicals, advanced intermediates, APIs and HPAPIs including ADC toxins. A dedicated site having more than 40 years’ experience in high potent compounds, with state-of-the-art containment systems and capability to handle broad range of chemistry from grams to kilos scale, including preparative-HPLC, makes Minakem a partner of choice in HPAPI and ADC toxins development and supply across the full product life cycle.
MUNIT is a consultancy company, operating in the field of MICRONIZATION of Active Pharmaceutical Ingredients (APIs), High Potent APIs, Cytotoxic and Cytostatic compounds, Inhalation products, Steroids, R&D compounds and Generics. In MUNIT we have combined the technical and commercial expertise of its affiliates Jetpharma SA (Switzerland) and Microchem Srl (Italy) making the best out of 40 years of leadership in the micronization sector.
The triangular company structure with its back-up potential, its technology transfer and the resulting flexibility is one of our unique features in the market and an important part of customers Business continuity plan.
With MUNITs lean organisation, its welcoming and customer orientated attitude, we are able to guarantee best service, high efficiency and punctuality to our customers worldwide.
PPD, part of Thermo Fisher Scientific, provides laboratory services that combine high-quality scientific expertise with industry-leading technologies supported by a commitment to exceptional quality to deliver integrated analytical services to the pharmaceutical landscape. Our customers benefit from comprehensive laboratory services backed by our more than 35 years of experience as a clinical research organization. Recognized as a global industry leader in accelerating promising medicines from early development through regulatory approval and market access, we serve pharma, biotech, medical device and government organizations with custom-tailored solutions, including full-service partnerships and functional service partnerships. As a strategic partner in clinical development and analytical services, we apply cutting edge technologies, therapeutic expertise and a firm commitment to quality to help customers deliver life-changing therapies.
Quanta BioDesign's dPEG® platform is founded upon discrete MW PEGs, which enable assembly of unique structures with single-molecule precision and without the liabilities associated with hydrophobic carbon-based linkers. Broadly speaking, ADCs combine an antibody's antigen-targeting properties with a payload's cell-killing properties. The dPEG® product line facilitates linker architectures that enhance a conjugate's tumor-targeting properties by altering its physicochemistry, pharmacokinetics, and biodistribution (See Chemical Linkers in Antibody Drug Conjugates, Royal Society of Chemistry, 2021). Tailoring these properties, through the optimal incorporation of dPEG® components, to shift in vivo delivery from off-target to tumor-targeted pathways has the potential to improve therapeutic margins.
ReachBio provides primary cell biology contract research services to the drug development and life science research community. With a special focus on hematopoietic (blood and bone marrow) primary cell systems, our platform is broad and includes predictive and investigative toxicology, immunology, efficacy testing, cell bank development, biomarker selection, flow cytometry/cell sorting, and assay development and. ReachBio has developed two distinct assay platforms to assess cytotoxicity caused by ADCs.
Sterling Pharma Solutions
Sterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO), with 50 years’ experience in small molecule API development and manufacturing services. In April 2021 Sterling acquired ADC Bio, a UK based biotechnology company specialising in antibody drug conjugates and bioconjugation. Together, as Sterling Pharma Solutions, the teams have developed an integrated service offering for existing and potential customers, which combines ADC Bio’s expertise with Sterling’s high potency small molecule expertise.
Sterling has four facilities employing more than 800 people: its HQ in Dudley, Northumberland, UK; a dedicated bioconjugation and ADCs facility in Deeside, North Wales, UK; and two sites in the US, in Cary, North Carolina and Germantown, Wisconsin.